Biopharma financing activity is showing a clear rebound in early 2026, with Q1 total financings reported at $22.82 billion—up sharply year over year despite a softer quarter relative to Q4 2025. The data point to renewed risk appetite across public and private markets following a slower 2025. Companies are also continuing to pursue IPO paths or pre-IPO funding to underwrite late-stage development plans, including programmatic expansions where timing to pivotal milestones is critical. For biotech leadership teams, the takeaway is that capital access is improving, but selectivity remains: investors continue to favor assets with clinical momentum, regulatory progress, or credible pathways to registrational evidence. The finance backdrop helps set expectations for how quickly companies can move into Phase 3 and how competition for high-quality pipeline assets may intensify as 2026 unfolds.